Overall survival and immune responses with sipuleucel-T and enzalutamide: STRIDE study.
Petrylak D, Drake C, Pieczonka C, Corman J, Garcia J, Dunshee C, Van Mouwerik T, Tyler R, Chang N, Quinn D. Overall survival and immune responses with sipuleucel-T and enzalutamide: STRIDE study. Journal Of Clinical Oncology 2018, 36: 246-246. DOI: 10.1200/jco.2018.36.6_suppl.246.Peer-Reviewed Original ResearchDisease progressionMetastatic castration-resistant prostate cancerCastration-resistant prostate cancerKaplan-Meier analysisNew safety concernsMedian followBaseline characteristicsOverall survivalPSA responseMedian ageClinical outcomesHormonal agentsProstate cancerClinical impactLaboratory valuesSTRIDE studyImmune responseLarger studySipuleucelWkSafety concernsFirst studyImmunotherapyPatientsFollow